tradingkey.logo
搜尋

Inotiv Inc

NOTV
添加自選
0.293USD
-0.016-5.11%
交易中 美東報價延遲15分鐘
10.09M總市值
虧損本益比TTM

Inotiv Inc

0.293
-0.016-5.11%
查看詳細走勢圖
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-5.11%

5天

-0.27%

1月

+19.76%

6月

-71.51%

今年開始到現在

-47.80%

1年

-85.62%

TradingKey Inotiv Inc股票評分

單位: USD 更新時間: 2026-05-14

操作建議

Inotiv Inc當前公司基本面數據相對穩定,最新ESG揭露屬於行業中等水平。增長潛力較大。當前估值合理,在生物技術與醫療研究行業排名150/382位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為3.00。中期看,股價處於平穩狀態。近一個月,市場表現較強,基本面評分較高,但較強的走勢沒有得到技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Inotiv Inc評分

相關信息

行業排名
150 / 382
全市場排名
272 / 4482
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Inotiv Inc亮點

亮點風險
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
估值高估
公司最新PE估值-0.12,處於3年歷史高位
機構減倉
最新機構持股8.11M股,環比減少37.19%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉87.15K股
活躍度增加
近期活躍度增加,過去20天平均換手率0.82

分析師目標

基於 2 分析師
買入
評級
3.000
目標均價
+855.41%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Inotiv Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Inotiv Inc簡介

Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
公司代碼NOTV
公司Inotiv Inc
CEOLeasure (Robert W)
網址https://www.inotiv.com/
KeyAI